Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine 20 mg tablet bioequivalence study versus BILAXTEN in healthy Thai adults under fasting conditions
TCTR20260809002Phase 1Not yet recruiting
- Sponsor
- Dr. Sasitorn Kittivoravitkul
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bilastine in allergic rhinitis (AR) and urticaria (2 arms), sponsored by Dr. Sasitorn Kittivoravitkul. Primary endpoints: Maximum plasma concentration (Cmax), Area under the plasma concentration-time curve from dosing to last observed concentration (AUC0-t) and 2 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
bilastine
03
Conditions
allergic rhinitis (AR)urticaria
Beyond the preview
Go deeper on TCTR20260809002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260809002.